Showing results (41-50 of 71) with videos related to
Sort By:
Pageof 8
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 6, 2017
Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable MelanomaJason Chesney, Igor Puzanov, Frances Collichio, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 28, 2019
Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 TrialCeleste Lebbé, Nicolas Meyer, Laurent Mortier, et al.Cancers|July 3, 2020
Pimasertib Versus Dacarbazine in Patients With Unresectable NRAS-Mutated Cutaneous Melanoma: Phase II, Randomized, Controlled Trial with CrossoverCeleste Lebbé, Caroline Dutriaux, Thierry Lesimple, et al.Clinical and Translational Medicine|March 22, 2024
PROM2 overexpression induces metastatic potential through epithelial-to-mesenchymal transition and ferroptosis resistance in human cancersJustine Paris, Claire Wilhelm, Celeste Lebbé, et al.Journal for Immunotherapy of Cancer|May 17, 2020
Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trialSandra P D'Angelo, Shailender Bhatia, Andrew S Brohl, et al.Nature Medicine|October 6, 2020
Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-iReinhard Dummer, Celeste Lebbé, Victoria Atkinson, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 16, 2017
Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced MelanomaMario Sznol, Pier Francesco Ferrucci, David Hogg, et al.The Lancet. Oncology|February 7, 2017
Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trialCorneel Coens, Stefan Suciu, Vanna Chiarion-Sileni, et al.Blood Advances|December 12, 2022
Characteristics of circulating KSHV-infected viroblasts during active KSHV+ multicentric Castleman diseaseGregoire Martin de Frémont, Anthony Vanjak, Zineb Sbihi, et al.European Journal of Cancer (Oxford, England : 1990)|January 14, 2020
European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics - Update 2019Claus Garbe, Teresa Amaral, Ketty Peris, et al.Pageof 8